vs
dLocal Ltd（DLO）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
dLocal Ltd的季度营收约是REPLIGEN CORP的1.7倍（$337.9M vs $197.9M），dLocal Ltd净利率更高（16.5% vs 6.7%，领先9.8%），dLocal Ltd同比增速更快（65.2% vs 13.6%），dLocal Ltd自由现金流更多（$99.8M vs $17.6M）
dLocal是一家总部位于乌拉圭的金融科技企业，专注于提供跨境支付解决方案，搭建全球商户与新兴市场之间的支付链路，助力国际商户顺畅接入新兴市场本地支付网络，高效开展跨境业务。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
DLO vs RGEN — 直观对比
营收规模更大
DLO
是对方的1.7倍
$197.9M
营收增速更快
DLO
高出51.6%
13.6%
净利率更高
DLO
高出9.8%
6.7%
自由现金流更多
DLO
多$82.3M
$17.6M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $337.9M | $197.9M |
| 净利润 | $55.6M | $13.3M |
| 毛利率 | 34.3% | 52.5% |
| 营业利润率 | 18.6% | 9.0% |
| 净利率 | 16.5% | 6.7% |
| 营收同比 | 65.2% | 13.6% |
| 净利润同比 | 87.3% | 143.9% |
| 每股收益（稀释后） | $0.18 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DLORGEN
| Q4 25 | $337.9M | $197.9M | ||
| Q3 25 | $282.5M | $188.8M | ||
| Q2 25 | — | $182.4M | ||
| Q1 25 | — | $169.2M | ||
| Q4 24 | $204.5M | $174.1M | ||
| Q3 24 | $185.8M | $154.9M | ||
| Q2 24 | — | $154.1M | ||
| Q1 24 | — | $151.3M |
净利润DLORGEN
| Q4 25 | $55.6M | $13.3M | ||
| Q3 25 | $141.3M | $14.9M | ||
| Q2 25 | — | $14.9M | ||
| Q1 25 | — | $5.8M | ||
| Q4 24 | $29.7M | $-30.3M | ||
| Q3 24 | $90.8M | $-654.0K | ||
| Q2 24 | — | $3.3M | ||
| Q1 24 | — | $2.1M |
毛利率DLORGEN
| Q4 25 | 34.3% | 52.5% | ||
| Q3 25 | 36.5% | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | 40.9% | 26.1% | ||
| Q3 24 | 42.1% | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率DLORGEN
| Q4 25 | 18.6% | 9.0% | ||
| Q3 25 | 19.7% | 8.9% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | 20.7% | -17.7% | ||
| Q3 24 | 22.1% | -5.1% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 1.3% |
净利率DLORGEN
| Q4 25 | 16.5% | 6.7% | ||
| Q3 25 | 50.0% | 7.9% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 3.4% | ||
| Q4 24 | 14.5% | -17.4% | ||
| Q3 24 | 48.9% | -0.4% | ||
| Q2 24 | — | 2.2% | ||
| Q1 24 | — | 1.4% |
每股收益（稀释后）DLORGEN
| Q4 25 | $0.18 | $0.24 | ||
| Q3 25 | $0.17 | $0.26 | ||
| Q2 25 | — | $0.26 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | $0.09 | $-0.55 | ||
| Q3 24 | $0.09 | $-0.01 | ||
| Q2 24 | — | $0.06 | ||
| Q1 24 | — | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $719.9M | $767.6M |
| 总债务越低越好 | $86.7M | $542.2M |
| 股东权益账面价值 | $569.4M | $2.1B |
| 总资产 | $1.5B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.15× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资DLORGEN
| Q4 25 | $719.9M | $767.6M | ||
| Q3 25 | $604.5M | $748.7M | ||
| Q2 25 | — | $708.9M | ||
| Q1 25 | — | $697.2M | ||
| Q4 24 | $425.2M | $757.4M | ||
| Q3 24 | $560.5M | $784.0M | ||
| Q2 24 | — | $809.1M | ||
| Q1 24 | — | $780.6M |
总债务DLORGEN
| Q4 25 | $86.7M | $542.2M | ||
| Q3 25 | $63.1M | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $39.8M | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DLORGEN
| Q4 25 | $569.4M | $2.1B | ||
| Q3 25 | $504.7M | $2.1B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | $489.0M | $2.0B | ||
| Q3 24 | $457.0M | $2.0B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.0B |
总资产DLORGEN
| Q4 25 | $1.5B | $2.9B | ||
| Q3 25 | $1.4B | $2.9B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $2.9B | ||
| Q4 24 | $1.2B | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $2.8B |
负债/权益比DLORGEN
| Q4 25 | 0.15× | 0.26× | ||
| Q3 25 | 0.12× | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.08× | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $100.4M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $99.8M | $17.6M |
| 自由现金流率自由现金流/营收 | 29.5% | 8.9% |
| 资本支出强度资本支出/营收 | 0.2% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.80× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $378.7M | $93.9M |
8季度趋势，按日历期对齐
经营现金流DLORGEN
| Q4 25 | $100.4M | $25.7M | ||
| Q3 25 | $315.0M | $48.1M | ||
| Q2 25 | — | $28.6M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | $-141.1M | $39.2M | ||
| Q3 24 | $108.3M | $49.3M | ||
| Q2 24 | — | $42.2M | ||
| Q1 24 | — | $44.7M |
自由现金流DLORGEN
| Q4 25 | $99.8M | $17.6M | ||
| Q3 25 | $313.4M | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | $-141.6M | $33.6M | ||
| Q3 24 | $107.1M | $42.3M | ||
| Q2 24 | — | $37.4M | ||
| Q1 24 | — | $36.4M |
自由现金流率DLORGEN
| Q4 25 | 29.5% | 8.9% | ||
| Q3 25 | 110.9% | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | -69.2% | 19.3% | ||
| Q3 24 | 57.6% | 27.3% | ||
| Q2 24 | — | 24.3% | ||
| Q1 24 | — | 24.0% |
资本支出强度DLORGEN
| Q4 25 | 0.2% | 4.1% | ||
| Q3 25 | 0.6% | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | 0.2% | 3.2% | ||
| Q3 24 | 0.7% | 4.5% | ||
| Q2 24 | — | 3.1% | ||
| Q1 24 | — | 5.5% |
现金转化率DLORGEN
| Q4 25 | 1.80× | 1.93× | ||
| Q3 25 | 2.23× | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | -4.75× | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
